Imagine trying to test a new medicine but only having a handful of people in the world who have the disease. Instead of struggling to find more patients, this project creates 'digital twins' and computer simulations to predict how a drug will work. It's like using a high-tech flight simulator to prove a plane is safe before it ever leaves the ground.
Drug developers for rare diseases struggle to get regulatory approval because patient groups are too small for traditional clinical trials. This leads to limited treatment options and high failure rates in the evidence-gathering phase.
The project is building virtual patient cohorts, extrapolation models for treatment effects, and regulatory evidence-assessment tools.
If you are an orphan drug developer dealing with tiny patient groups that make traditional trials impossible — this project developed virtual cohorts and simulation methods that allow you to generate the evidence needed for approval.
If you are a pediatric medicine startup dealing with high variability in child patient responses — this project developed improved extrapolation models that help predict treatment effects across different age groups.
If you are an RWD analytics firm dealing with fragmented registry data — this project developed evidence synthesis tools that combine registry data with computational models to support regulatory decisions.
Based on available project data, no specific pricing or implementation costs are provided as the project is currently in the research and development phase.
Yes, the project is specifically designed for the European industry to exploit in drug development, with industrial partners like Roche and Novartis providing use cases for validation.
Based on available project data, specific licensing terms are not mentioned, but the project involves a consortium of 17 partners including 4 industry entities.
It provides regulators with evidence-tools, workflows, and assessment criteria to make informed decisions based on small sample sizes in rare diseases.
The project runs from 2024-01-01 to 2028-12-31, suggesting the full set of tools will be ready by the end of 2028.
The consortium is well-balanced for commercial translation, featuring a 24% industry ratio with 4 industrial partners, including global giants Roche and Novartis. With 17 partners across 9 countries, the project combines academic rigor (6 universities, 4 research institutes) with practical regulatory and commercial application, ensuring the resulting tools meet actual market needs.
Contact the Institut National de la Santé et de la Recherche Médicale (INSERM) in France.
Contact us to track the validation of these in silico trial tools for your pipeline.
